Interbody fusion rapidly adopted for spondylolisthesis

Interbody fusion rapidly adopted for spondylolisthesis

(HealthDay)—Interbody fusion (IF) has been rapidly adopted for the treatment of degenerative spondylolisthesis (DS), according to a study published in the Sept. 1 issue of Spine.

Christopher K. Kepler, M.D., M.B.A., from Thomas Jefferson University in Philadelphia, and colleagues used the American Board of Orthopaedic Surgery database to describe trends for patients who underwent surgery for DS from 1999 to 2011. Patients undergoing uninstrumented fusion, fusion with posterior instrumentation, fusion using interbody device, or decompression without fusion were included.

The researchers found that the annual number of cases doubled over the study period, with a total of 5,639 cases. Throughout the study period there was a significant increase in the percentage of cases treated with IF (13.6 percent in 1999 to 2001 versus 32 percent in 2009 to 2011; P < 0.001). In 2003, the percentage of DS cases treated with posterolateral fusion peaked followed by a decrease concomitant with the increasing rate of IF. The rates of posterolateral fusion and posterolateral fusion with IF were 40 and 37 percent, respectively, in 2011. The highest rate of IF was seen in the Northwest (41 percent), more than 10 and 23 percent higher than any other region and than the Southeast, respectively (both P < 0.001).

"Despite little evidence guiding treatment strategy for DS, national patterns have changed dramatically during the past 13 years," conclude the authors.
Relevant financial activities outside the submitted work were disclosed.

Explore further

Instrumented spinal fusion method impacts infection rate

More information: Abstract
Full Text (subscription or payment may be required)
Journal information: Spine

Copyright © 2014 HealthDay. All rights reserved.

Citation: Interbody fusion rapidly adopted for spondylolisthesis (2014, September 12) retrieved 1 December 2021 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors